Novavax Inc (NVAX)

9.605 -1.22 (-11.23%) USD  |  NASDAQ  |  Jan 08, 16:00
9.60 0.00 (0.00%) After-Hours: 20:00
More

Novavax SG&A Expense (Quarterly): 70.75M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for NVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc 3.244B
Moderna Inc 281.00M
Inovio Pharmaceuticals Inc 8.614M
Baxter International Inc 754.00M
Halozyme Therapeutics Inc 41.24M